Interactions between Immunoglobulin like receptors and the Peptidome in the Allogeneic Hematopoietic Stem Cell Transplantation in the Cytomegalovirus context. A mini review.
Article Sidebar
Published
Feb 28, 2024
Downloads
Download data is not yet available.
Submit your own article
Register as an author to reserve your spot in the next issue of the Medical Research Archives.
Author RegistrationJoin the Society
The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.
Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.
MembershipMain Article Content
Abstract
The Natural Killer cells are innate lymphoid cells that play essential roles in defense against viral and parasitic infections, elimination of tumor cells, regulation of adaptive immunity through cytotoxicity, and cytokine secretion. Fundamental knowledge about the regulation of Natural Killer cells can be applied to study their function in patients undergoing hematopoietic stem cell transplantation, with or without Cytomegalovirus reactivation. The function of Natural Killer cells is governed by a repertoire of receptors responsible for initiating intracellular activating or inhibitory signaling. The balance of this signaling directs the cytotoxic activity of these cells, as well as cell proliferation and cytokine release.Understanding the interaction of receptors expressed on the surface of Natural Killer cells with their ligands expressed on target cells is a topic of discussion in the context of alloreactivity and the graft-versus-leukemia effect in transplant patients. Recent investigations have shown that KIR/HLA interactions go beyond affinity and describe that many of them depend on the peptide being presented by the HLA at that moment. Analysis of the peptidome (HLA class I + bound peptide) has demonstrated that some Natural Killer cell receptors are peptide-dependent. Therefore, understanding these interactions by considering the entire Natural Killer cell receptor + HLA class I + peptide complex is crucial in the reestablishment of immune cells after hematopoietic stem cell transplantation, especially in the context of Cytomegalovirus reactivation, which is very common in these patients. Hence, the aim of this study is to deepen our understanding of the specificity of interactions between human Natural Killer cell KIR receptors and the peptidome in the context of Cytomegalovirus reactivation after allogeneic, related, HLA-compatible hematopoietic stem cell transplantation without T-cell depletion. For the analysis of interactions between Natural Killer cell receptors and peptidomes, specific peptide libraries for HLA class I alleles will be created to evaluate the specificities of interactions between KIR + HLA class I + peptide.
Keywords:
Natural Killer cells, peptidome, activating and inhibitory receptors, HLA class I molecules, recognition specificity
Article Details
How to Cite
CARDOZO, Daniela Maira et al.
Interactions between Immunoglobulin like receptors and the Peptidome in the Allogeneic Hematopoietic Stem Cell Transplantation in the Cytomegalovirus context. A mini review..
Medical Research Archives, [S.l.], v. 12, n. 2, feb. 2024.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/5144>. Date accessed: 23 nov. 2024.
doi: https://doi.org/10.18103/mra.v12i2.5144.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Vivier E., Artis D., Colonna M., Diefenbach A., Di Santo JP, Eberl G., Koyasu S., Locksley RM, McKenzie ANJ, Mebius RE, et al. Células linfóides inatas: 10 anos depois. Célula. 2018; 174:1054–1066. doi: 10.1016/j.cell.2018.07.017.
2. Lopes N, Galluso J, Escalière B, Carpentier S, Kerdiles YM, Vivier E. Tissue-specific transcriptional profiles and heterogeneity of natural killer cells and group 1 innate lymphoid cells. Cell Rep Med. 2022 Nov 15;3(11):100812. doi: 10.1016/j.xcrm.2022.100812. PMID: 36384102; PMCID: PMC9729827.
3. Gasteiger G., Fan X., Dikiy S., Lee SY, Rudensky AY Residência tecidual de células linfóides inatas em órgãos linfóides e não linfóides. Ciência. 2015; 350 :981–985. doi: 10.1126/science.aac9593.
4. Seillet C., Brossay L., Vivier E. Assassinos naturais ou ILC1s? Essa é a questão. Curr. Opinião. Imunol. 2021; 68 :48–53. doi: 10.1016/j.coi.2020.08.009.
5. Bryceson YT, Março ME, Barbeiro DF, Ljunggren HG, Long EO. Polarização e degranulação citolítica de grânulos controlada por diferentes receptores em células NK em repouso. J Exp Med (2005) 202(7):1001–12. DOI: 10.1084/jem.20051143
6. Bashirova AA1, Martin MP, McVicar DW, Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet. 2006;7:277-300.
7. Hsu KC, Dupont B. Natural killer cell receptors: regulating innate immune responses to hematologic malignancy. Semin Hematol. 2005 Apr;42(2):91-103. doi: 10.1053/j.seminhematol.2005.01.010.
PMID: 15846575.
8. Karvouni M, Vidal-Manrique M, Lundqvist A, Alici E. Engineered NK Cells Against Cancer and Their Potential Applications Beyond. Front Immunol. 2022 Feb 15;13:825979. doi: 10.3389/fimmu.2022.825979.
PMID: 35242135; PMCID: PMC8887605.
9. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003 Aug 18;198(4):557-67. doi: 10.1084/jem.20030788. Epub 2003 Aug 11. PMID: 12913096; PMCID: PMC2194180.
10. Hilton HG, Norman PJ, Nemat-Gorgani N, Goyos A, Hollenbach JA, Henn BM, et al.. Loss and gain of natural killer cell receptor function in an african hunter-gatherer population. PLoS Genet. (2015) 11:e1005439. 10.1371/journal.pgen.1005439
11. Hilton HG, Guethlein LA, Goyos A, Nemat-Gorgani N, Bushnell DA, Norman PJ, et al.. Polymorphic HLA-C receptors balance the functional characteristics of KIR haplotypes. J Immunol. (2015) 195:3160–70.
12. Pende D, Falco M, Vitale M, Cantoni C, Vitale C, Munari E, Bertaina A, Moretta F, Del Zotto G, Pietra G, Mingari MC, Locatelli F, Moretta L. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Front Immunol. 2019 May 28;10:1179. doi: 10.3389/fimmu.2019.01179. PMID: 31231370; PMCID: PMC6558367.
13. Sim MJW, Brennan P, Wahl KL, Lu J, Rajagopalan S, Sun PD, Long EO. Innate receptors with high specificity for HLA class I-peptide complexes. Sci Immunol. 2023 Sep 8;8(87):eadh1781. doi: 10.1126/sciimmunol.adh1781.
Epub 2023 Sep 8. PMID: 37683038.
14. Zaitoua AJ, Kaur A, Raghavan M. Variations in MHC class I antigen presentation and immunopeptidome selection pathways. F1000Res. 2020 Sep 28;9:F1000 Faculty Rev-1177. doi: 10.12688/f1000research.26935.1. PMID: 33014341; PMCID: PMC7525337.
15. Raghavan M, Geng J: HLA-B polymorphisms and intracellular assembly modes. Mol Immunol. 2015;68(2 Pt A):89–93. 10.1016/j.molimm.2015.07.007
16. Garcia KC, Adams EJ. How the T cell receptor sees antigen--a structural view. Cell. 2005;122(3):333–6.
17. Malnati MS, et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science. 1995;267(5200):1016–8.
18. Peruzzi M, et al. Peptide sequence requirements for the recognition of HLA-B*2705 by specific natural killer cells. J Immunol. 1996;157(8):3350–6.
19. Storkus WJ, et al. Peptide-induced modulation of target cell sensitivity to natural killing. J Immunol. 1992;149(4):1185–90.
20. Zappacosta F, et al. Peptides isolated from HLA-Cw*0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc Natl Acad Sci U S A. 1997;94(12):6313–8.
21. Rajagopalan S, Long EO. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J Exp Med. 1997;185(8):1523–8.
22. Boyington JC, et al. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature. 2000;405(6786):537–43.
23. Fan QR, Long EO, Wiley DC. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol. 2001;2(5):452–60.
24. Stewart CA, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005;102(37):13224–9.
25. Sim MJ, et al. Canonical and Cross-reactive Binding of NK Cell Inhibitory Receptors to HLA-C Allotypes Is Dictated by Peptides Bound to HLA-C. Front Immunol. 2017;8:193.
26. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev. 2006 Dec;214:186-201.
27. Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther. 2009 Dec;8(23):2211-20. Epub 2009 Dec 28.
28. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009 Mar 26;113(13):3119-29. doi: 10.1182/blood-2008-06-164103. Epub 2008 Oct 22.J. M.
29. Alter G, et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature. 2011;476(7358):96–100
30. van Teijlingen NH, et al. Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03:04 and modulate primary natural killer cell function. AIDS. 2014;28(10):1399–408.
31. Holzemer A, et al. Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa. PLoS Med. 2015;12(11):e1001900. discussion e00.
32. S. I. Khakoo, C. L. Thio, M. P. Martin, C. R. Brooks, X. Gao, J. Astemborski, J. Cheng, J. J. Goedert, D. Vlahov, M. Hilgartner, S. Cox, A. M. Little, G. J. Alexander, M. E. Cramp, S. J. O'Brien, W. M. Rosenberg, D. L. Thomas, M. Carrington, HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305, 872–874 (2004).
33. S. E. Hiby, J. J. Walker, K. M. O'Shaughnessy, C. W. G. Redman, M. Carrington, J. Trowsdale, A. Moffett, Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 200, 957–965 (2004).
34. L. Ruggeri, M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, M. F. Martelli, A. Velardi, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097–2100 (2002).
35. G. W. Nelson, M. P. Martin, D. Gladman, J. Wade, J. Trowsdale, M. Carrington, Cutting edge: Heterozygote advantage in autoimmune disease: Hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J. Immunol. 173, 4273–4276 (2004).
36. Venstrom, G. Pittari, T. A. Gooley, J. H. Chewning, S. Spellman, M. Haagenson, M. M. Gallagher, M. Malkki, E. Petersdorf, B. Dupont, K. C. Hsu, HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Engl. J. Med. 367, 805–816 (2012).
37. Cardozo DM, Marangon AV, da Silva RF, Aranha FJP, Visentainer JEL, Bonon SHA, Costa SCB, Miranda ECM, de Souza CA, Guimarães F. Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in improving outcomes of haematopoietic stem cell transplantation from HLA-matched sibling donor for treatment of myeloid malignancies. Hum Immunol. 2016 Oct;77(10):861-868. doi: 10.1016/j.humimm.2016.07.003. Epub 2016 Jul 6. PMID: 27394130.
38. Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev. 2001 Jun;181:170-84. doi: 10.1034/j.1600-065x.2001.1810114.x. PMID: 11513138.
39. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006 Jan 1;107(1):159-66. doi: 10.1182/blood-2005-04-1351. Epub 2005 Sep 8. PMID: 16150947; PMCID: PMC1895346.
40. Caligiuri MA. Human natural killer cells. Blood. 2008 Aug 1;112(3):461-9. doi: 10.1182/blood-2007-09-077438.
PMID: 18650461; PMCID: PMC2481557.
41. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990 Jul;11(7):237-44. doi: 10.1016/0167-5699(90)90097-s. PMID: 2201309.
42. García-Lora A, Martinez M, Pedrinaci S, Garrido F. Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. Cancer Immunol Immunother. 2003 Jan;52(1):59-64. doi: 10.1007/s00262-002-0336-9. Epub 2002 Oct 17. PMID: 12536241.
43. Schanoski AS, Cavalcanti TC, Campos CB, Viera-Matos AN, Rettori O, Guimarães F. Walker 256 tumor MHC class I expression during the shift from A variant to the immunogenic AR variant. Cancer Lett. 2004 Jul 28;211(1):119-27. doi: 10.1016/j.canlet.2004.01.023.
PMID: 15194224.
44. Gao F, Ye Y, Gao Y, Huang H, Zhao Y. Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation. Front Immunol. 2020 Sep 2;11:2022. doi: 10.3389/fimmu.2020.02022. PMID: 32983145; PMCID: PMC7493622.
45. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol. (2011) 155:14–29. 10.1111/j.1365-2141.2011.08823.x.
46. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al.. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. (2002) 295:2097–100. 10.1126/science.1068440.
47. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004 Jan 1;172(1):644-50. doi: 10.4049/jimmunol.172.1.644. PMID: 14688377.
48. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, et al.. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. (2009) 113:726–32. 10.1182/blood-2008-07-171926.
49. Green ML, Leisenring W., Xie H., Mast TC, Cui Y., Sandmaier BM, et al. (2016). Carga viral e mortalidade do citomegalovírus após transplante de células-tronco hematopoiéticas na era da terapia preventiva: um estudo de coorte retrospectivo. Lancet Haematol. < a i=3>3 e119–e127. 10.1016/S2352-3026(15)00289-6.
50. F. Cichocki, et al. Adaptive NK cell reconstitution is associated with better clinical outcomes JCI Insight, 4 (2) (2019).
51. A. Rashidi, et al. The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. Blood Adv., 3 (16) (2019).
52. N. Apiwattanakul, et al., CMV-reactive NK cells in pediatric post-hematopoietic stem cell transplant Transplant. Proc., 52 (1) (2020), pp. 353-359.
53. P. Dogra, et al. Tissue determinants of human NK cell development, function, and residence. Cell, 180 (4) (2020), pp. 749-763.
54. Hammer Q, Rückert T, Borst EM, Dunst J, Haubner A, Durek P, Heinrich F, Gasparoni G, Babic M, Tomic A, Pietra G, Nienen M, Blau IW, Hofmann J, Na IK, Prinz I, Koenecke C, Hemmati P, Babel N, Arnold R, Walter J, Thurley K, Mashreghi MF, Messerle M, Romagnani C. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat Immunol. 2018 May;19(5):453-463. doi: 10.1038/s41590-018-0082-6. Epub 2018 Apr 9. PMID: 29632329.
55. Faridi RM, and Agrawal S (2011). Killer immunoglobulin-like receptors (KIRs) and HLA-C allorecognition patterns implicative of dominant activation of natural killer cells contribute to recurrent miscarriages. Hum. Reprod 26, 491–497.
56. Stewart CA, Laugier-Anfossi F, Vély F, Saulquin X, Riedmuller J, Tisserant A, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A (2005) 102(37):13224–9. 10.1073/pnas.0503594102
57. Fadda L, Borhis G, Ahmed P, Cheent K, Pageon SV, Cazaly A, et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A (2010) 107(22):10160–5. 10.1073/pnas.0913745107
58. Chen C, Busson M, Rocha V, Appert ML, Lepage V, Dulphy N, et al.. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant. (2006) 38:437–44. 10.1038/sj.bmt.1705468
59. Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, et al.. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood. (2006) 107:1230–2. 10.1182/blood-2005-03-1039
60. Zaia JA, Sun JY, Gallez-Hawkins GM, Thao L, Oki A, Lacey SF, et al.. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant. (2009) 15:315–25. 10.1016/j.bbmt.2008.11.030
61. Wu X, He J, Wu D, Bao X, Qiu Q, Yuan X, et al.. KIR and HLA-Cw genotypes of donor-recipient pairs influence the rate of CMV reactivation following non-T-cell deleted unrelated donor hematopoietic cell transplantation. Am J Hematol. (2009) 84:776–7. 10.1002/ajh.21527
62. Tomblyn M, Young JA, Haagenson MD, Klein JP, Trachtenberg EA, Storek J, et al.. Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biol Blood Marrow Transplant. (2010) 16:1155–61. 10.1016/j.bbmt.2010.02.024
63. Gallez-Hawkins GM, Franck AE, Li X, Thao L, Oki A, Gendzekhadze K, et al.. Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection. Biol Blood Marrow Transplant. (2011) 17:1662–72. 10.1016/j.bbmt.2011.04.008
64. Mancusi A, Ruggeri L, Urbani E, Pierini A, Massei MS, Carotti A, et al.. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. Blood. (2015) 125:3173–82. 10.1182/blood-2014-09-599993
65. Wrona E, Borowiec M, Potemski P. CAR-NK Cells in the Treatment of Solid Tumors. Int J Mol Sci. 2021 May 31;22(11):5899. doi: 10.3390/ijms22115899. PMID: 34072732; PMCID: PMC8197981.
66. Sabbah M, Jondreville L, Lacan C, Norol F, Vieillard V, Roos-Weil D, Nguyen S. CAR-NK Cells: A Chimeric Hope or a Promising Therapy? Cancers (Basel). 2022 Aug 8;14(15):3839. doi: 10.3390/cancers14153839. PMID: 35954502; PMCID: PMC9367380.
2. Lopes N, Galluso J, Escalière B, Carpentier S, Kerdiles YM, Vivier E. Tissue-specific transcriptional profiles and heterogeneity of natural killer cells and group 1 innate lymphoid cells. Cell Rep Med. 2022 Nov 15;3(11):100812. doi: 10.1016/j.xcrm.2022.100812. PMID: 36384102; PMCID: PMC9729827.
3. Gasteiger G., Fan X., Dikiy S., Lee SY, Rudensky AY Residência tecidual de células linfóides inatas em órgãos linfóides e não linfóides. Ciência. 2015; 350 :981–985. doi: 10.1126/science.aac9593.
4. Seillet C., Brossay L., Vivier E. Assassinos naturais ou ILC1s? Essa é a questão. Curr. Opinião. Imunol. 2021; 68 :48–53. doi: 10.1016/j.coi.2020.08.009.
5. Bryceson YT, Março ME, Barbeiro DF, Ljunggren HG, Long EO. Polarização e degranulação citolítica de grânulos controlada por diferentes receptores em células NK em repouso. J Exp Med (2005) 202(7):1001–12. DOI: 10.1084/jem.20051143
6. Bashirova AA1, Martin MP, McVicar DW, Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet. 2006;7:277-300.
7. Hsu KC, Dupont B. Natural killer cell receptors: regulating innate immune responses to hematologic malignancy. Semin Hematol. 2005 Apr;42(2):91-103. doi: 10.1053/j.seminhematol.2005.01.010.
PMID: 15846575.
8. Karvouni M, Vidal-Manrique M, Lundqvist A, Alici E. Engineered NK Cells Against Cancer and Their Potential Applications Beyond. Front Immunol. 2022 Feb 15;13:825979. doi: 10.3389/fimmu.2022.825979.
PMID: 35242135; PMCID: PMC8887605.
9. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003 Aug 18;198(4):557-67. doi: 10.1084/jem.20030788. Epub 2003 Aug 11. PMID: 12913096; PMCID: PMC2194180.
10. Hilton HG, Norman PJ, Nemat-Gorgani N, Goyos A, Hollenbach JA, Henn BM, et al.. Loss and gain of natural killer cell receptor function in an african hunter-gatherer population. PLoS Genet. (2015) 11:e1005439. 10.1371/journal.pgen.1005439
11. Hilton HG, Guethlein LA, Goyos A, Nemat-Gorgani N, Bushnell DA, Norman PJ, et al.. Polymorphic HLA-C receptors balance the functional characteristics of KIR haplotypes. J Immunol. (2015) 195:3160–70.
12. Pende D, Falco M, Vitale M, Cantoni C, Vitale C, Munari E, Bertaina A, Moretta F, Del Zotto G, Pietra G, Mingari MC, Locatelli F, Moretta L. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Front Immunol. 2019 May 28;10:1179. doi: 10.3389/fimmu.2019.01179. PMID: 31231370; PMCID: PMC6558367.
13. Sim MJW, Brennan P, Wahl KL, Lu J, Rajagopalan S, Sun PD, Long EO. Innate receptors with high specificity for HLA class I-peptide complexes. Sci Immunol. 2023 Sep 8;8(87):eadh1781. doi: 10.1126/sciimmunol.adh1781.
Epub 2023 Sep 8. PMID: 37683038.
14. Zaitoua AJ, Kaur A, Raghavan M. Variations in MHC class I antigen presentation and immunopeptidome selection pathways. F1000Res. 2020 Sep 28;9:F1000 Faculty Rev-1177. doi: 10.12688/f1000research.26935.1. PMID: 33014341; PMCID: PMC7525337.
15. Raghavan M, Geng J: HLA-B polymorphisms and intracellular assembly modes. Mol Immunol. 2015;68(2 Pt A):89–93. 10.1016/j.molimm.2015.07.007
16. Garcia KC, Adams EJ. How the T cell receptor sees antigen--a structural view. Cell. 2005;122(3):333–6.
17. Malnati MS, et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science. 1995;267(5200):1016–8.
18. Peruzzi M, et al. Peptide sequence requirements for the recognition of HLA-B*2705 by specific natural killer cells. J Immunol. 1996;157(8):3350–6.
19. Storkus WJ, et al. Peptide-induced modulation of target cell sensitivity to natural killing. J Immunol. 1992;149(4):1185–90.
20. Zappacosta F, et al. Peptides isolated from HLA-Cw*0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc Natl Acad Sci U S A. 1997;94(12):6313–8.
21. Rajagopalan S, Long EO. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J Exp Med. 1997;185(8):1523–8.
22. Boyington JC, et al. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature. 2000;405(6786):537–43.
23. Fan QR, Long EO, Wiley DC. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol. 2001;2(5):452–60.
24. Stewart CA, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005;102(37):13224–9.
25. Sim MJ, et al. Canonical and Cross-reactive Binding of NK Cell Inhibitory Receptors to HLA-C Allotypes Is Dictated by Peptides Bound to HLA-C. Front Immunol. 2017;8:193.
26. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev. 2006 Dec;214:186-201.
27. Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther. 2009 Dec;8(23):2211-20. Epub 2009 Dec 28.
28. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009 Mar 26;113(13):3119-29. doi: 10.1182/blood-2008-06-164103. Epub 2008 Oct 22.J. M.
29. Alter G, et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature. 2011;476(7358):96–100
30. van Teijlingen NH, et al. Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03:04 and modulate primary natural killer cell function. AIDS. 2014;28(10):1399–408.
31. Holzemer A, et al. Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa. PLoS Med. 2015;12(11):e1001900. discussion e00.
32. S. I. Khakoo, C. L. Thio, M. P. Martin, C. R. Brooks, X. Gao, J. Astemborski, J. Cheng, J. J. Goedert, D. Vlahov, M. Hilgartner, S. Cox, A. M. Little, G. J. Alexander, M. E. Cramp, S. J. O'Brien, W. M. Rosenberg, D. L. Thomas, M. Carrington, HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305, 872–874 (2004).
33. S. E. Hiby, J. J. Walker, K. M. O'Shaughnessy, C. W. G. Redman, M. Carrington, J. Trowsdale, A. Moffett, Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 200, 957–965 (2004).
34. L. Ruggeri, M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, M. F. Martelli, A. Velardi, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097–2100 (2002).
35. G. W. Nelson, M. P. Martin, D. Gladman, J. Wade, J. Trowsdale, M. Carrington, Cutting edge: Heterozygote advantage in autoimmune disease: Hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J. Immunol. 173, 4273–4276 (2004).
36. Venstrom, G. Pittari, T. A. Gooley, J. H. Chewning, S. Spellman, M. Haagenson, M. M. Gallagher, M. Malkki, E. Petersdorf, B. Dupont, K. C. Hsu, HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Engl. J. Med. 367, 805–816 (2012).
37. Cardozo DM, Marangon AV, da Silva RF, Aranha FJP, Visentainer JEL, Bonon SHA, Costa SCB, Miranda ECM, de Souza CA, Guimarães F. Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in improving outcomes of haematopoietic stem cell transplantation from HLA-matched sibling donor for treatment of myeloid malignancies. Hum Immunol. 2016 Oct;77(10):861-868. doi: 10.1016/j.humimm.2016.07.003. Epub 2016 Jul 6. PMID: 27394130.
38. Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev. 2001 Jun;181:170-84. doi: 10.1034/j.1600-065x.2001.1810114.x. PMID: 11513138.
39. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006 Jan 1;107(1):159-66. doi: 10.1182/blood-2005-04-1351. Epub 2005 Sep 8. PMID: 16150947; PMCID: PMC1895346.
40. Caligiuri MA. Human natural killer cells. Blood. 2008 Aug 1;112(3):461-9. doi: 10.1182/blood-2007-09-077438.
PMID: 18650461; PMCID: PMC2481557.
41. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990 Jul;11(7):237-44. doi: 10.1016/0167-5699(90)90097-s. PMID: 2201309.
42. García-Lora A, Martinez M, Pedrinaci S, Garrido F. Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. Cancer Immunol Immunother. 2003 Jan;52(1):59-64. doi: 10.1007/s00262-002-0336-9. Epub 2002 Oct 17. PMID: 12536241.
43. Schanoski AS, Cavalcanti TC, Campos CB, Viera-Matos AN, Rettori O, Guimarães F. Walker 256 tumor MHC class I expression during the shift from A variant to the immunogenic AR variant. Cancer Lett. 2004 Jul 28;211(1):119-27. doi: 10.1016/j.canlet.2004.01.023.
PMID: 15194224.
44. Gao F, Ye Y, Gao Y, Huang H, Zhao Y. Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation. Front Immunol. 2020 Sep 2;11:2022. doi: 10.3389/fimmu.2020.02022. PMID: 32983145; PMCID: PMC7493622.
45. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol. (2011) 155:14–29. 10.1111/j.1365-2141.2011.08823.x.
46. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al.. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. (2002) 295:2097–100. 10.1126/science.1068440.
47. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004 Jan 1;172(1):644-50. doi: 10.4049/jimmunol.172.1.644. PMID: 14688377.
48. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, et al.. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. (2009) 113:726–32. 10.1182/blood-2008-07-171926.
49. Green ML, Leisenring W., Xie H., Mast TC, Cui Y., Sandmaier BM, et al. (2016). Carga viral e mortalidade do citomegalovírus após transplante de células-tronco hematopoiéticas na era da terapia preventiva: um estudo de coorte retrospectivo. Lancet Haematol. < a i=3>3 e119–e127. 10.1016/S2352-3026(15)00289-6.
50. F. Cichocki, et al. Adaptive NK cell reconstitution is associated with better clinical outcomes JCI Insight, 4 (2) (2019).
51. A. Rashidi, et al. The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. Blood Adv., 3 (16) (2019).
52. N. Apiwattanakul, et al., CMV-reactive NK cells in pediatric post-hematopoietic stem cell transplant Transplant. Proc., 52 (1) (2020), pp. 353-359.
53. P. Dogra, et al. Tissue determinants of human NK cell development, function, and residence. Cell, 180 (4) (2020), pp. 749-763.
54. Hammer Q, Rückert T, Borst EM, Dunst J, Haubner A, Durek P, Heinrich F, Gasparoni G, Babic M, Tomic A, Pietra G, Nienen M, Blau IW, Hofmann J, Na IK, Prinz I, Koenecke C, Hemmati P, Babel N, Arnold R, Walter J, Thurley K, Mashreghi MF, Messerle M, Romagnani C. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat Immunol. 2018 May;19(5):453-463. doi: 10.1038/s41590-018-0082-6. Epub 2018 Apr 9. PMID: 29632329.
55. Faridi RM, and Agrawal S (2011). Killer immunoglobulin-like receptors (KIRs) and HLA-C allorecognition patterns implicative of dominant activation of natural killer cells contribute to recurrent miscarriages. Hum. Reprod 26, 491–497.
56. Stewart CA, Laugier-Anfossi F, Vély F, Saulquin X, Riedmuller J, Tisserant A, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A (2005) 102(37):13224–9. 10.1073/pnas.0503594102
57. Fadda L, Borhis G, Ahmed P, Cheent K, Pageon SV, Cazaly A, et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A (2010) 107(22):10160–5. 10.1073/pnas.0913745107
58. Chen C, Busson M, Rocha V, Appert ML, Lepage V, Dulphy N, et al.. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant. (2006) 38:437–44. 10.1038/sj.bmt.1705468
59. Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, et al.. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood. (2006) 107:1230–2. 10.1182/blood-2005-03-1039
60. Zaia JA, Sun JY, Gallez-Hawkins GM, Thao L, Oki A, Lacey SF, et al.. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant. (2009) 15:315–25. 10.1016/j.bbmt.2008.11.030
61. Wu X, He J, Wu D, Bao X, Qiu Q, Yuan X, et al.. KIR and HLA-Cw genotypes of donor-recipient pairs influence the rate of CMV reactivation following non-T-cell deleted unrelated donor hematopoietic cell transplantation. Am J Hematol. (2009) 84:776–7. 10.1002/ajh.21527
62. Tomblyn M, Young JA, Haagenson MD, Klein JP, Trachtenberg EA, Storek J, et al.. Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biol Blood Marrow Transplant. (2010) 16:1155–61. 10.1016/j.bbmt.2010.02.024
63. Gallez-Hawkins GM, Franck AE, Li X, Thao L, Oki A, Gendzekhadze K, et al.. Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection. Biol Blood Marrow Transplant. (2011) 17:1662–72. 10.1016/j.bbmt.2011.04.008
64. Mancusi A, Ruggeri L, Urbani E, Pierini A, Massei MS, Carotti A, et al.. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. Blood. (2015) 125:3173–82. 10.1182/blood-2014-09-599993
65. Wrona E, Borowiec M, Potemski P. CAR-NK Cells in the Treatment of Solid Tumors. Int J Mol Sci. 2021 May 31;22(11):5899. doi: 10.3390/ijms22115899. PMID: 34072732; PMCID: PMC8197981.
66. Sabbah M, Jondreville L, Lacan C, Norol F, Vieillard V, Roos-Weil D, Nguyen S. CAR-NK Cells: A Chimeric Hope or a Promising Therapy? Cancers (Basel). 2022 Aug 8;14(15):3839. doi: 10.3390/cancers14153839. PMID: 35954502; PMCID: PMC9367380.